Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently announced that it has received alignment from the U.S. Food and Drug Administration (FDA) on the design of a …
Ocugen Gains FDA Alignment for Phase 3 Trial of Retinitis Pigmentosa Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a Pennsylvania-based biopharmaceutical company, has scored a significant regulatory milestone this week with the U.S. Food and Drug Administration (FDA) granting Regenerative Medicine …
Ocugen’s OCU400 Earns FDA’s RMAT Designation, Enhancing Prospects for Retinitis Pigmentosa Treatment Read More
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) this week announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of its NeuroSite™ Coil Placement Accessory. The state-of-the-art tool, designed to …
Neuronetics Secures FDA Clearance for NeuroSite, Streamlining Mental Health Treatments Read More
EXTON, PA — In a move that strengthens its position as a global leader in innovative solutions for injectable drug administration systems, West Pharmaceutical Services, Inc. (NYSE: WST) recently announced …
West Pharmaceutical Services Expands Injectable Drug Portfolio with FDA Cleared Vial2Bag Advanced 13mm Admixture Device Read More MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM), a leading medical technology company specializing in innovative solutions for mental health, has announced that its NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy System …
Neuronetics’ NeuroStar TMS Therapy System Receives Advanced Approval in Japan, Paving the Way for Enhanced Depression Treatment Read More
PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) recently announced that its Investigational New Drug application (IND) for CT-0525 has been cleared by the U.S. Food and Drug Administration (FDA). …
Carisma Therapeutics Receives FDA Clearance for Groundbreaking CAR-Monocyte Cellular Therapy Read More
The Federal Trade Commission (FTC) recently unveiled its Fiscal Year 2023 Agency Financial Report, spotlighting the agency’s accomplishments in safeguarding consumers and fostering competition. The report also reemphasizes the FTC’s …
FTC Releases Fiscal Year 2023 Agency Financial Report Read More
The U.S. Food and Drug Administration recently approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as …
FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes Read More